Product Description
Pioglitazone is used with a diet and exercise program and sometimes with other medications, to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood). Pioglitazone is in a class of medications called thiazolidinediones.
Mechanisms of Action: PPAR-g Agonist, STAT5 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: Asia Pacific
Company Founding Year: 1781
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Austria, Brazil, Denmark, France, Germany, Italy, Japan, Norway, Poland, Spain
Active Clinical Trial Count: 9
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: ANCA Vasculitis|Glomerulonephritis|Type 2 Diabetes
Phase 2: COVID-19|Obesity|Polycystic Ovary Syndrome|Wet Macular Degeneration
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07444424 |
D7260C00024 | P1 |
Not yet recruiting |
Type 2 Diabetes|Obesity |
2026-07-02 |
88% |
2026-03-03 |
Primary Endpoints |
2018-003817-16 |
Kinarus wet AMD treat and extend study | P2 |
Active, not recruiting |
Wet Macular Degeneration |
2020-07-28 |
2022-03-13 |
Treatments |
|
NCT05946564 |
RENATO | P3 |
Recruiting |
Glomerulonephritis|ANCA Vasculitis |
2027-04-24 |
2024-07-12 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT05028140 |
PIEMONTE | P3 |
Recruiting |
Type 2 Diabetes |
2026-07-01 |
18% |
2025-12-11 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
2024-518527-29-00 |
SPIOMET4HEALTH | P2 |
Recruiting |
Polycystic Ovary Syndrome |
2026-02-25 |
2025-05-02 |
Treatments |
|
2022-500244-37-00 |
KIN001-204 | P2 |
Completed |
COVID-19 |
2025-04-24 |
2025-05-02 |
Treatments |
|
jRCT2071250139 |
jRCT2071250139 | P1 |
Recruiting |
Unknown |
2026-07-31 |
|||
2023-508924-36-00 |
CT-L03-301 | P3 |
Recruiting |
Type 2 Diabetes |
2026-05-31 |
2025-05-02 |
Treatments |
|
ACTRN12619001580167p |
2006-7041-83/hah | P2 |
Not yet recruiting |
Obesity |
None |